← Back to Search

Increasing Willingness and Uptake of COVID-19 Testing and Vaccination for Coronavirus Infection

N/A
Waitlist Available
Led By Mohsen Bazargan, PhD
Research Sponsored by Charles Drew University of Medicine and Science
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Identify as Latino/Hispanic or African American/Black
Reside in one of the six collaborating public housing
Timeline
Screening 3 weeks
Treatment Varies
Follow Up intervention: 3 months; follow-up point: 6 months post-intervention
Awards & highlights

Study Summary

COVID-2019 Testing and Vaccination Among African American and Latinx Public Housing Residents

Eligible Conditions
  • Coronavirus Infection

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~intervention: 3 months; follow-up point: 6 months post-intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and intervention: 3 months; follow-up point: 6 months post-intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Participants Achieving Decreased Levels of COVID-19 Mistrust and Barriers Using the NIH Toolbox Surveys on COVID-19
Percentage of Participants Achieving Decreased Levels of COVID-19 Risk Using the NIH Toolbox Surveys on COVID-19
Influenza virus vaccine

Side effects data

From 2012 Phase 3 trial • 6104 Patients • NCT01346592
27%
Injection site pain
25%
Pyrexia
14%
Upper respiratory tract infection
14%
Decreased appetite
14%
Diarrhea
10%
Injection site erythema
9%
Nasopharyngitis
9%
Irritability postvaccinal
9%
Headache
8%
Vomiting
8%
Injection site induration
7%
Hypersomnia
7%
Myalgia
7%
Injection site swelling
7%
Fatigue
6%
Crying
6%
Injection site hemorrhage
4%
Gastroenteritis
1%
Pneumonia
1%
Animal Bite
100%
80%
60%
40%
20%
0%
Study treatment Arm
ATIV (6 to <72 Months)
TIV (6 to <72 Months)
Comparator TIV (6 to <72 Months)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Increasing Uptake of COVID-19 Testing and VaccinationExperimental Treatment1 Intervention
This is a pre-experimental "one group pretest-posttest" design to improve COVID-19 associated health outcomes and willingness and uptake toward testing and vaccination among 310 Hispanic and African American public housing residents in South Los Angeles. The proposed intervention will employ (1) culturally sensitive, (2) theoretically based intervention that will be jointly delivered by our COVID-19 health ambassadors and our researchers. We will use the Information, Motivation, and Behavioral Skills (IMB) model and the Transtheoretical Model to implement the intervention.

Find a Location

Who is running the clinical trial?

Charles Drew University of Medicine and ScienceLead Sponsor
51 Previous Clinical Trials
6,637 Total Patients Enrolled
Mohsen Bazargan, PhDPrincipal InvestigatorCharles R. Drew University of Medicine & Science
2 Previous Clinical Trials
150 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~0 spots leftby Nov 2025